Skip to content

The Joymain far-red insomnia treatment apparatus microcirculation evaluation of safety and efficacy: a randomized, blank controlled, crossover design, multi-center clinical trial

The Joymain far-red insomnia treatment apparatus microcirculation evaluation of safety and efficacy: a randomized, blank controlled, crossover design, multi-center clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TTRCC-12002450
Enrollment
Unknown
Registered
2012-08-19
Start date
2012-08-08
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Microcirculation

Interventions

Sponsors

Henan College of Traditional Chinese Medicine, First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Three high population screening microcirculation mildly abnormal, moderately abnormal patients.(Of Microcirculation Points at 2-8 between the patients); 2. 18-60 years of age, male or female; 3. Voluntary participation in the trial, and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Normal microcirculation, generally normal or severe abnormalities of patients; 2. Skin injury healed, bleeding tendencies, surgery or serious trauma stress situation; 3. Patients with severe hypertension [systolic blood pressure >=24KPa (180mmHg) and / or diastolic blood pressure >= 14KPa (105mmHg); 4. Implanted metal objects implanted medical electronic equipment, such as pacemakers and other persons; 5. With severe primary cardiac, liver, lung, kidney, blood, or affect the survival of serious diseases, such as cancer or AIDS; renal dysfunction; 6. Severe hypoproteinemia and serious systemic infection; 7. Mental disorders can not give fully informed consent; 8. Suspect or does have a history of alcohol and drug abuse; 9. According to the investigator's judgment, could easily lead to loss to follow to reduce the possibility of inclusion or so into the complex set of other lesions, such as working conditions change frequently; 10. Pregnancy, breast-feeding women; 11. Allergies, such as two or more drugs or a history of food allergies, or known allergy to the product used in the trial; 12. Participated in other clinical trials within three months.

Design outcomes

Primary

MeasureTime frame
Microcirculation check point;

Secondary

MeasureTime frame
Pipe loop shape integral;State points of the blood flow;Loop weeks state point;

Countries

China

Contacts

Public ContactJacky Zhang
sqz5259@163.com+86 13666600715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026